$MLYS

Mineralys Therapeutics, Inc. reported its Q4 2025 earnings with a focus on significant advancements in their clinical trials for hypertension treatments. The company has made considerable progress towards regulatory submission, which has led to an optimistic outlook from analysts. However, there were concerns regarding increased operational costs that may affect profitability in the short term. Overall, the company has positioned itself favorably within the competitive landscape of hypertension therapies. Their innovations and strategic partnerships are expected to drive future growth, particularly in the upcoming fiscal year.